Skip to search formSkip to main contentSkip to account menu

sorafenib 200 MG Oral Tablet [Nexavar]

Known as: Nexavar 200 MG Oral Tablet, SORAFENIB 200 mg ORAL TABLET, FILM COATED [Nexavar] 
National Institutes of Health

Related topics

Related topics

12 relations
Croscarmellose SodiumMagnesium stearateNexavarOral Tablet

Broader (1)

Nexavar Pill

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin
Background/Aim: The aim of the present study was to examine the effect of orally administered sorafenib (Nexavar®), sunitinib… 
Review
2015
Review
2015
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma
Sorafenib (Nexavar®) is the first tyrosine kinase inhibitor to be approved for the treatment of radioactive iodine (RAI… 
2013
2013
Yttirum-90 resin microspheres as an adjunct to sorafenib in patients with unresectable HCC: a retrospective study for evaluation of survival benefit and adverse events
2012
2012
CPI-613, AN INVESTIGATIONAL NOVEL ANTI-CANCER AGENT, PROVIDES LONG-TERM STABLE DISEASE WITHOUT SIGNIFICANT ADVERSE EFFECTS IN A PATIENT WITH STAGE IV RELAPSED HEPATOCELLULAR CARCINOMA
The current case study describes the safety and prolonged therapeutic effect of an investigational drug (CPI-613) in a patient… 
2011
2011
Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma
Abstract 1653 Introduction: A significant proportion of Hodgkin lymphoma (HL) patients refractory to first-line chemotherapy or… 
Review
2008
Review
2008
Current available therapies and future directions in the treatment of malignant gliomas
The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing… 
Review
2007
Review
2007
Adjuvant Therapy in Renal Cell Carcinoma: Where Are We?
2007
2007
Looking Ahead in Renal Cell Carcinoma: Integrating New Agents in the Armamentarium of the Urologist
2007
2007
New Perspectives: An Oral Multikinase Inhibitor in Patients with Advanced RCC
2007
2007
Wirksamkeit von Multikinaseinhibitoren in der Therapie des fortgeschrittenen Nierenzellkarzinoms
ZusammenfassungGalten bisher aufgrund der weitgehenden Chemotherapieresistenz des Nierenzellkarzinoms Zytokin-basierte… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)